StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report sent to investors on Monday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
Shares of NASDAQ:TTNP opened at $5.33 on Monday. The stock’s fifty day simple moving average is $5.85 and its two-hundred day simple moving average is $6.30. Titan Pharmaceuticals has a 1-year low of $4.24 and a 1-year high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last released its quarterly earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Read More
- Five stocks we like better than Titan Pharmaceuticals
- Election Stocks: How Elections Affect the Stock Market
- When Is the Best Time to Invest in Mutual Funds?
- How to Invest in the FAANG Stocks
- Is NVIDIA Stock in a Correction or Consolidation?
- High Flyers: 3 Natural Gas Stocks for March 2022
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
